Response to: ‘Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results’

Sir,

We thank Dr Dave for his valuable comments and suggestions and appreciate his interest in our manuscript.¹ We agree with the author that it would be appropriate to also provide the median value for the number of prior injections and duration of treatment, in addition to the standard deviation. The study included patients who had received 23.8±18.8 (median 21.5) prior ranibizumab or bevacizumab injections over the previous 28±20.5 (median 24) months.

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account

Continue with Google

Continue with ORCiD